Next Article in Journal
Induced Fit Docking into a SERT Homology Model
Previous Article in Journal
QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 77
Issue 7
10.3797/scipharm.oephg.21.PO-03
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Ligand Based Screening Tools for Insulin Receptor Activating Compounds

by
D. DIGLES
1,*,
V. M. DIRSCH
2 and
G. F. ECKER
1
1
Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090, Vienna, Austria
2
Department of Pharmacognosy, University of Vienna, Althanstraße 14, 1090, Vienna, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2009, 77(7), 202; https://doi.org/10.3797/scipharm.oephg.21.PO-03
Submission received: 16 April 2009 / Accepted: 16 April 2009 / Published: 16 April 2009
Versions Notes

Abstract

Current treatments of type 2 diabetes mellitus have sometimes severe side effects. Therefore, the identification of new treatments is still an urgent need. The binding of insulin to the extracellular part of the insulin receptor is a key step in the insulin signalling pathway. As type 2 diabetes is characterized among others by a resistance of cells against insulin, activating the insulin receptor might be an interesting approach. In 1999, Zhang et al. discovered a small molecule from a fungal extract which activates the human insulin receptor by binding directly to its intracellular domain [1]. This compound (L-783,281 or demethylasterriquinone B-1, DMAQ-B1) was shown to lower blood glucose levels in mouse models of type 2 diabetes mellitus.

Share and Cite

MDPI and ACS Style

DIGLES, D.; DIRSCH, V.M.; ECKER, G.F. Ligand Based Screening Tools for Insulin Receptor Activating Compounds. Sci. Pharm. 2009, 77, 202. https://doi.org/10.3797/scipharm.oephg.21.PO-03

AMA Style

DIGLES D, DIRSCH VM, ECKER GF. Ligand Based Screening Tools for Insulin Receptor Activating Compounds. Scientia Pharmaceutica. 2009; 77(Posters (PO)):202. https://doi.org/10.3797/scipharm.oephg.21.PO-03

Chicago/Turabian Style

DIGLES, D., V. M. DIRSCH, and G. F. ECKER. 2009. "Ligand Based Screening Tools for Insulin Receptor Activating Compounds" Scientia Pharmaceutica 77, Posters (PO): 202. https://doi.org/10.3797/scipharm.oephg.21.PO-03

APA Style

DIGLES, D., DIRSCH, V. M., & ECKER, G. F. (2009). Ligand Based Screening Tools for Insulin Receptor Activating Compounds. Scientia Pharmaceutica, 77(Posters (PO)), 202. https://doi.org/10.3797/scipharm.oephg.21.PO-03

Article Metrics

Back to TopTop